LianBio entered into a clinical supply agreement with AstraZeneca for BBP-398 in EGGFR Mu NSCLC

CAR-T Digest - August 2020

12 Jul 2023: BBP-398 / Osimertinib / EGFR mutated NSCLC / LianBio / AstraZeneca: Announced a clinical supply agreement

LianBio announced a clinical supply agreement with AstraZeneca in China
Company plans to conduct multi-center Phase 1 trial to assess the safety and efficacy of BBP-398 (investigational SHP2 inhibitor) in combination with Osimertinib for the treatment of patients with EGFR-mutated NSCLC
- Trial to be initiated in H2’23
The trial will include a dose escalation phase, followed by expansion cohorts
“While EGFR inhibitors are a critical part of the standard of care, most patients eventually acquire resistance to these therapies. We believe BBP-398 is a differentiated SHP2 inhibitor with the potential to restore sensitivity to EGFR inhibitors when used in a combination setting.” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio